ORYZON raises its share capital by EUR 20 Million through a private placement
MADRID, SPAIN and CAMBRIDGE MA.
Oryzon Genomics, S.A. (MAD: ORY) ("Oryzon" or the "Company"), a clinical‐stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced the pricing of a capital increase of 6,666,667 new common shares (the “New Shares”) at a price of 3.00 euros per share, for an aggregate amount of EUR 20 million (the “Capital Increase”). The Capital Increase was carried out through a private placement aimed at qualified investors. The Company intends to use the net proceeds from the Capital Increase to finance the Company’s research and development of clinical pipeline candidates, for working capital and other general corporate purposes.